Every man with prostate cancer deserves to know his germline BRCA 1/2 status and recent changes now make that possible and easier than ever. Medicare has expanded coverage for BRACAnalysis CDx^® for men with prostate cancer who are eligible or may become eligible for treatment with Lynparza^® (olaparib). Knowing tour patient’s germline status early in the treatment journey not only helps guide treatment and management decisions, it could also qualify him for future, life-sustaining therapies should he progress to metastasis.

To learn more, click here.